doi: 10.1111/ejn.16278.
- PMID: 38385841
- DOI: 10.1111/ejn.16278
Abstract
Schizophrenia is a psychotic disorder with an increasing prevalence and incidence over the last two decades. The condition presents with a diverse array of positive, negative, and cognitive impairments. Conventional treatments often yield unsatisfactory outcomes, especially with negative symptoms. We investigated the role of prefrontocortical (PFC) N-methyl-D-aspartate receptors (NMDARs) in the pathophysiology and development of schizophrenia. We explored the potential therapeutic effects of cannabidiolic acid (CBDA) methyl ester (HU-580), an analogue of CBDA known to act as an agonist of the serotonin-1A receptor (5-HT1AR) and an antagonist of cannabinoid type 1 receptor (CB1R). C57BL/6 mice were intraperitoneally administered the NMDAR antagonist, dizocilpine (MK-801, .3 mg/kg) once daily for 17 days. After 7 days, they were concurrently given HU-580 (.01 or .05 μg/kg) for 10 days. Behavioural deficits were assessed at two time points. We conducted enzyme-linked immunosorbent assays to measure the concentration of PFC 5-HT1AR and CB1R. We found that MK-801 effectively induced schizophrenia-related behaviours including hyperactivity, social withdrawal, increased forced swim immobility, and cognitive deficits. We discovered that low-dose HU-580 (.01 μg/kg), but not the high dose (.05 μg/kg), attenuated hyperactivity, forced swim immobility and cognitive deficits, particularly in female mice. Our results revealed that MK-801 downregulated both CB1R and 5-HT1AR, an effect that was blocked by both low- and high-dose HU-580. This study sheds light on the potential antipsychotic properties of HU-580, particularly in the context of NMDAR-induced dysfunction. Our findings could contribute significantly to our understanding of schizophrenia pathophysiology and offer a promising avenue for exploring the therapeutic potential of HU-580 and related compounds in alleviating symptoms.
Keywords: MK-801, cannabidiolic acid methyl ester (HU-580), cannabinoid CB1 receptor, mouse model, schizophrenia, serotonin-1A receptor
© 2024 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
References
REFERENCES
-
- Albert, P. R. (2012). Transcriptional regulation of the 5-HT1A receptor: Implications for mental illness. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 367(1601), 2402-2415. https://doi.org/10.1098/rstb.2011.0376
-
- An, D., Peigneur, S., Hendrickx, L. A., & Tytgat, J. (2020). Targeting cannabinoid receptors: Current status and prospects of natural products. International Journal of Molecular Sciences, 21(14), 5064. https://doi.org/10.3390/ijms21145064
-
- Ballmaier, M., Bortolato, M., Rizzetti, C., Zoli, M., Gessa, G., Heinz, A., & Spano, P. (2007). Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology, 32(10), 2098-2107. https://doi.org/10.1038/sj.npp.1301344
-
- Balu, D. T. (2016). The NMDA receptor and schizophrenia: From pathophysiology to treatment. Advances in Pharmacology (San Diego, Calif.), 76, 351-382. https://doi.org/10.1016/bs.apha.2016.01.006
-
- Bambico, F. R., Lacoste, B., Hattan, P. R., & Gobbi, G. (2015). Father absence in the monogamous California mouse impairs social behavior and modifies dopamine and glutamate synapses in the medial prefrontal cortex. Cerebral Cortex (New York, N.Y.: 1991), 25(5), 1163-1175. https://doi.org/10.1093/cercor/bht310
